Phase III, single-arm study investigating the efficacy, safety, and tolerability of anagrelide as a second-line treatment in high-risk Japanese patients with essential thrombocythemia

Essential thrombocythemia (ET) is usually managed by anti-platelet therapy. European guidelines recommend that patients with ET at high risk of developing thrombohemorrhagic events should be placed on cytoreductive therapy (CRT). In Japan, hydroxycarbamide (HC) is the most widely used CRT; however,...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology 2014-10, Vol.100 (4), p.353-360
Main Authors: Kanakura, Yuzuru, Miyakawa, Yoshitaka, Wilde, Paul, Smith, Jonathan, Achenbach, Heinrich, Okamoto, Shinichiro
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Asian Continental Ancestry Group
Biological and medical sciences
Blood Platelets - metabolism
Blood Platelets - pathology
Female
Fibrinolytic Agents - administration & dosage
Fibrinolytic Agents - adverse effects
Hematologic and hematopoietic diseases
Hematology
Humans
Japan
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Male
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Oncology
Original Article
Platelet Count
Quinazolines - administration & dosage
Quinazolines - agonists
Risk Factors
Thrombocythemia, Essential - blood
Thrombocythemia, Essential - drug therapy
Thrombocythemia, Essential - pathology
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Essential thrombocythemia (ET) is usually managed by anti-platelet therapy. European guidelines recommend that patients with ET at high risk of developing thrombohemorrhagic events should be placed on cytoreductive therapy (CRT). In Japan, hydroxycarbamide (HC) is the most widely used CRT; however, treatment options for patients who become intolerant or refractory to initial treatment are limited. This study sought to determine the efficacy, safety, and tolerability of anagrelide in high-risk Japanese adults with ET who were intolerant or refractory to their first-line CRT. Fifty-three patients were enrolled in the study. Of those, 67.9 % had a platelet response (
ISSN:0925-5710
1865-3774
DOI:10.1007/s12185-014-1631-x